Olokizumab Shows Efficacy After Nonresponse to TNF Inhibitors

The most likely use of olokizumab in clinical practice, if it is approved, is for patients with inadequate responses to TNF inhibitors.
MDedge News

source https://www.medscape.com/viewarticle/981624?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?